Multiple Myeloma Epidemiology and Market Forecast by DelveInsight
(Albany, US) DelveInsight has launched a new report Multiple Myeloma Epidemiology
Multiple myeloma (MM) is a type of blood cancer that affects plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow (the soft, spongy tissue at the center of your bones), crowding out the normal plasma cells that help fight infection. These malignant plasma cells then produce an abnormal antibody called M protein, which offers no benefit to the body and may cause tumors, kidney damage, bone destruction, and impaired immune function. The hallmark characteristic of multiple myeloma is a high level of M protein in the blood.
DelveInsight’s ‘Multiple Myeloma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Get a free sample copy of basic structure of the report- https://www.delveinsight.com/sample-request/multiple-myeloma-epidemiology-forecast
Multiple myeloma can be difficult to diagnose. To form an accurate diagnosis, doctor will rely on a number of factors, including physical evaluation, symptoms, medical history, and the results of many different diagnostic tests. The initial evaluation to help confirm a diagnosis of multiple myeloma includes blood and urine tests as well as a bone marrow biopsy. Other tests include X-rays, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and positron-emission tomography (PET) scans. Genome sequencing can also provide additional information about the genetic mutations specific to cancer.
Key facts of the report
- As per “American Cancer Society”, Multiple myeloma is a relatively uncommon cancer. In the United States, the lifetime risk of getting multiple myeloma is 1 in 132 (0.76%).
- As per the “International Myeloma Foundation, 2018”, there are approximately 750,000 people living with myeloma worldwide, with approximately 180,000 patients in the United States.
- As per “Myeloma UK 2020”, Myeloma, also known as multiple myeloma, is a blood cancer arising from plasma cells. At any one time there are around 17,500 people living with myeloma in the UK. It accounts for 15% of blood cancers, and 2% of all cancers. Myeloma mainly affects those over the age of 65, however it has been diagnosed in people much younger.
Multiple Myeloma is a malignant disease characterized by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.
Multiple Myeloma Report Scope
- The report covers the descriptive overview of Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
- Comprehensive insight has been provided into the Multiple Myeloma epidemiology and treatment in the 8MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market.
Get a free sample copy of basic structure of the report- https://www.delveinsight.com/sample-request/multiple-myeloma-epidemiology-forecast
List of table of content
- Key Insights
- Executive Summary of Multiple Myeloma (MM)
- KOL Views
- SWOT Analysis of Multiple Myeloma (MM)
- Multiple Myeloma: Market Overview at a Glance
- Disease Background and Overview: Multiple Myeloma (MM)
- Diagnosis of Multiple Myeloma
- Epidemiology and Patient Population
- The United States Epidemiology
- EU-5 Epidemiology
- Japan Epidemiology
- China Epidemiology
- Treatment
- Unmet Needs
- Patient Journey of Multiple Myeloma
- Key Endpoints of MM Clinical Trials
- Marketed Therapies
- Emerging Therapies
- Multiple Myeloma (MM): Eight Major Market Analysis
- 8MM Market Size
- The United States Market Size
- EU-5 Market Size
- Japan Market Size
- China Market Size
- Market Access and Reimbursement of Multiple Myeloma (MM) Therapies
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.
- To understand the future market competition in the Multiple Myeloma market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan and China.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma market.
- To understand the future market competition in the Multiple Myeloma market.
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Shruti Thakur
+91-9650213330
Published at Thu, 12 Nov 2020 06:43:21 +0000